I'm interested in conversations about and I want to talk about
Know exactly what you want?
Show search

Notification

Error


Docetaxel and Dicyclomine

Email this conversation Print this conversation
User
Posted 26 Jan 2024 at 16:44
A paper in Cell Reports Medicine, 22nd January 2024, linked below, states that Docetaxel effectiveness can be extended by using Dicyclomine both before resistance and after resistance.  This was also reported in the Times last week.

................................................................

'Dicyclomine, a clinically available CHRM1-selective antagonist, reverts resistance and restricts the growth of multiple docetaxel-resistant CRPC cell lines and patient-derived xenografts. Our study reveals a CHRM1-dictated mechanism for docetaxel resistance and identifies a CHRM1-targeted combinatorial strategy for overcoming docetaxel resistance in PC.'

............

 

As this is a paper it presumably is some way off being a treatment.

 

 

 

 

Edited by member 30 Jan 2024 at 18:59  | Reason: Complete re-write based on finding the original report.

User
Posted 31 Jan 2024 at 10:25

Originally Posted by: Online Community Member

A paper in Cell Reports Medicine, 22nd January 2024, linked below, states that Docetaxel effectiveness can be extended by using Dicyclomine both before resistance and after resistance.  This was also reported in the Times last week.

................................................................

'Dicyclomine, a clinically available CHRM1-selective antagonist, reverts resistance and restricts the growth of multiple docetaxel-resistant CRPC cell lines and patient-derived xenografts. Our study reveals a CHRM1-dictated mechanism for docetaxel resistance and identifies a CHRM1-targeted combinatorial strategy for overcoming docetaxel resistance in PC.'

............

 

As this is a paper it presumably is some way off being a treatment.

 

 

The majority of the information is of excellent quality, and there are very few cases of very poor quality.

User
Posted 11 Sep 2025 at 09:58

Originally Posted by: Online Community Member

A paper in Cell Reports Medicine, 22nd January 2024, linked below, states that Docetaxel effectiveness can be extended by using Dicyclomine both before resistance and after resistance.  This was also reported in the Times last week.

................................................................

'Dicyclomine, a clinically available CHRM1-selective antagonist, reverts resistance and restricts the growth of multiple docetaxel-resistant CRPC cell lines and patient-derived xenografts. Our study reveals a CHRM1-dictated mechanism for docetaxel resistance and identifies a CHRM1-targeted combinatorial strategy for overcoming docetaxel resistance in PC.'

............

 

As this is a paper it presumably is some way off being a treatment.

 

 

 

 

Research shows that Dicyclomine can prolong the effectiveness of Docetaxel and help overcome drug resistance in the treatment of CRPC.

User
Posted 10 Dec 2025 at 04:11

Originally Posted by: Online Community Member

A paper in Cell Reports Medicine, 22nd January 2024, linked below, states that Docetaxel effectiveness can be extended by using Dicyclomine both before resistance and after resistance.  This was also reported in the Times last week.

................................................................

'Dicyclomine, a clinically available CHRM1-selective antagonist, reverts resistance and restricts the growth of multiple docetaxel-resistant CRPC cell lines and patient-derived xenografts. Our study reveals a CHRM1-dictated mechanism for docetaxel resistance and identifies a CHRM1-targeted combinatorial strategy for overcoming docetaxel resistance in PC.'

............

 

As this is a paper it presumably is some way off being a treatment. 

 

 

Interesting results, and it’s promising that dicyclomine may help overcome docetaxel resistance. But since this is still preclinical research, it’s far from being an approved treatment. We’ll need clinical trials to know if it’s safe and effective in patients.

 
Forum Jump  
Email this conversation Print this conversation

Join the online community now.

Click through to become a member and gain access to support, information and real time replies.




MenuTop ▲
©2025 Prostate Cancer UK